<DOC>
	<DOCNO>NCT01443078</DOCNO>
	<brief_summary>The purpose study test new approach use standard drug surgery patient lung cancer . This study find effect , good and/or bad , approach cancer . It routine give chemotherapy prior surgery patient type lung cancer , help keep come back . It also routine perform special type scan call PET scan . This PET scan measure active cancer use special tracer make sugar . In study , patient PET scan treat standard chemotherapy drug , either pemetrexed cisplatin cancer `` non-squamous '' cancer gemcitabine cisplatin cancer squamous cancer . In rare case , doctor decide give carboplatin instead cisplatin . In patient , repeat PET scan show tumor decrease complete standard chemotherapy go surgery . In patient , repeat PET scan show tumor decrease enough . For patient , routine practice proceed surgery . This research study test whether switch standard treatment pemetrexed cisplatin gemcitabine cisplatin different treatment call vinorelbine docetaxel safe effective . Vinorelbine docetaxel also standard chemotherapy drug work different way pemetrexed gemcitabine cisplatin .</brief_summary>
	<brief_title>Neoadjuvant Platinum-based Chemotherapy Patients With Resectable , Non-small Cell Lung Cancer With Switch Chemotherapy Alternative Nonresponders ( NEOSCAN )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologic confirmation NSCLC MSKCC Stages IB , IIA , IIB , IIIA IIIB NSCLC Primary tumor must measure ≥ 2 cm CT imaging ( per PERCIST guideline ) Primary tumor must FDGavid SUVmax &gt; 4.5 ( consistent PERCIST guideline ) Patients must candidate resection curative intent Age ≥ 18 year Karnofsky performance status ≥ 70 % Normal bone marrow function leukocytes ≥ 3,000/μl absolute neutrophil count ≥ 1,500/μl platelet ≥100,000/μl hemoglobin ≥9gm/dl . Adequate hepatic function Total bilirubin ≤1.5 x ULN AST ≤ 1.5 x UNL , ALT ≤ 1.5 x ULN Alkaline phosphatase ≤ 1.5x ULN Women childbearing age must negative pregnancy test Men woman childbearing potential must willing use effective contraception treatment least 3 month thereafter Patients must ability understand willingness sign write informed consent document Patients must receive investigational agent History myocardial infarction unstable angina within past 12 month Patients peripheral neuropathy &gt; grade 1 Other serious illness medical condition include unstable cardiac disease require treatment , history significant neurologic psychiatric disorder ( include psychotic disorder , dementia , seizure ) , active uncontrolled infection . Patients diabetes mellitus require insulin therapy ( per PERCIST guideline ) Patients third space fluid adequately control drainage Women pregnant breastfeed Psychiatric illness social situation would limit compliance study requirement Patients know HIV infection require antiretroviral medication AIDS Baseline subjective hearing deficit , even require hear aid intervention , interfere activity daily live ( CTCAE grade 2 high ) Baseline renal function &lt; 60 ml/min calculate equation Cockcroft Gault use patient 's age , weight ( kg ) , serum creatinine ( mg/dl ) . Congestive heart failure New York Heart Association functional classification &gt; II , characterize fatigue , dyspnea symptom limit activity daily life . Selection Pemetrexed versus Gemcitabine : Patients treat pemetrexed must meet following criterion : Nonsquamous histology Patients must ability interrupt nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day ( 5 day longacting NSAIDs ) , day , 2 day follow administration pemetrexed Patients must ability take folic acid , Vitamin B12 , dexamethasone accord protocol Patient refuse take cisplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Pemetrexed ( Altima )</keyword>
	<keyword>Taxotere ( Docetaxel )</keyword>
	<keyword>Vinorelbine Tartrate ( Navelbine )</keyword>
	<keyword>Stage IB-III</keyword>
	<keyword>non squamous</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>11-106</keyword>
</DOC>